Prof. Bernd Jilma, MD obtained his MD degree at the Medical Faculty of the Vienna University in 1993 and holds a tenure position as Professor for Internal Medicine and Clinical Pharmacology at the Medical University of Vienna. He has a long standing interest in mechanistic and clinical pharmacology studies with anticoagulants and antiplatelet drugs and has established a human endotoxin challenge model at his institution. Additionally, he has served in various functions at the European Medicines Agency providing scientific advice related to new drugs in development. Efficient clinical trial design is one of his many current interests. Major contributions in the Orphan Drugs Sector include the design of phase I-III trials that have led to the marketing authorisation applications of caplacizumab in thrombotic thrombocytopenic purpura and sutimlimab for cold agglutinin disease. His contributions to the scientific field have been published in the most prestigious as well as other high-impact journals.